Patent intelligence · US
US 12331099
VEGF antagonist formulations suitable for intravitreal administration
VEGF antagonist formulations suitable for intravitreal administration
Patent details — US 12331099
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 17, 2025
- Expiration
- Jun 12, 2045
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Claims
- 30
- CPC classes
- A61K, A61K38/179, A61K38/1793, A61K47/02
Quick answer
US 12331099 (VEGF antagonist formulations suitable for intravitreal administration) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K38/179, A61K38/1793, A61K47/02, A61K47/10, A61K47/26
More from REGENERON PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421512
CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
granted -
US 12421317
Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies
granted -
US 12421315
CLL-1 targeted immunotherapies
granted -
US 12419963
Diels-Alder conjugation methods
granted -
US 12415856
EGFR x CD28 multispecific antibodies
granted -
US 12410442
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
granted -
US 12404505
Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
granted -
US 12402611
Genetically modified mice and engraftment
granted
Frequently asked questions
What is US patent 12331099?
US 12331099 (VEGF antagonist formulations suitable for intravitreal administration) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12331099?
REGENERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 837 pharmaceutical patents for this assignee.
When does US 12331099 expire?
Our index shows an expiration date of Jun 12, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.